Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
Catalyst Pharmaceuticals, Inc.'s share was trading at $22.96 as of January 15th. CPRX's trailing and forward P/E were 13.43 and 10.34 respectively according to Yahoo Finance. Copyright: dolgachov / 123RF Stock Photo Catalyst Pharmaceuticals (CPRX) is positioned as a leading rare-disease biopharma with a focused dual-pillar strategy centered on FIRDAPSE and AGAMREE. FIRDAPSE (amifampridine) is the only FDA-approved therapy for Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and pediatric patients six and older, leveraging a unique mechanism that enhances acetylcholine release to restore muscle function. Its efficacy is backed by two positive Phase 3 studies, and patent protection extends through February 2035, effectively creating a near-monopoly in its market. The company is driving growth through promotion of a recently approved 100mg maximum daily dose and expanding outreach to capture cancer-associated LEMS patients. AGAMREE (vamorolone), approved for Duchenne Muscular Dys
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Does Forbes' Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? [Yahoo! Finance]Yahoo! Finance
- Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap CompaniesGlobeNewswire
- The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) [Yahoo! Finance]Yahoo! Finance
- The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)GlobeNewswire
CPRX
Earnings
- 11/5/25 - Beat
CPRX
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- CPRX's page on the SEC website